Literature DB >> 15826485

Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.

Antonio Cuadrado1, Aitor Orive, Covadonga García-Suárez, Agustín Domínguez, Jose Carlos Fernández-Escalante, Javier Crespo, Fernando Pons-Romero.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is characterized by an excessive accumulation of fatty acids and triglycerides within the cytoplasm of the hepatocytes of non-alcohol users. The natural history varies according to the initial histological diagnosis. A current consideration is that cryptogenic cirrhosis may be representative of a late stage of non-alcoholic steatohepatitis (NASH), which has lost its features of necroinflammatory activity and steatosis in up to 80% of patients. Since NASH is able to progress to cirrhosis, hepatocellular carcinoma (HCC) development may be an end-stage of this disease. We report below two clinical cases of patients diagnosed with NASH who developed HCC. The relationship between NAFLD and HCC is reviewed.

Entities:  

Mesh:

Year:  2005        PMID: 15826485     DOI: 10.1381/0960892053576596

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  22 in total

1.  Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Pavel Vladimirovich Korita; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

Review 2.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

3.  Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude.

Authors:  Hidekatsu Kuroda; Keisuke Kakisaka; Naohisa Kamiyama; Takayoshi Oikawa; Mio Onodera; Kei Sawara; Kanta Oikawa; Ryujin Endo; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

4.  Sensitivity of chemical shift-encoded fat quantification to calibration of fat MR spectrum.

Authors:  Xiaoke Wang; Diego Hernando; Scott B Reeder
Journal:  Magn Reson Med       Date:  2015-04-04       Impact factor: 4.668

5.  T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis.

Authors:  Catherine D G Hines; Alex Frydrychowicz; Gavin Hamilton; Dana L Tudorascu; Karl K Vigen; Huanzhou Yu; Charles A McKenzie; Claude B Sirlin; Jean H Brittain; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2011-04       Impact factor: 4.813

Review 6.  Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.

Authors:  Francesca Lodato; Giuseppe Mazzella; Davide Festi; Francesco Azzaroli; Antonio Colecchia; Enrico Roda
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

7.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

8.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 9.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

Review 10.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.